Echo Therapeutics announces the availability of independent research report

Jan 23 2010

Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, is pleased to announce the availability of an independent research report that was issued yesterday with a "Strong Speculative Buy" recommendation and a 12 to 18 month price target of $4.50. The report is authored by Stephen M. Dunn, Senior Managing Director, Research, and William D. Dawson, Senior Vice President, Research, for LifeTech Capital, a division of Aurora Capital LLC. It can be found online at www.lifetechcapital.com/reports.htm.

The report describes Echo's commercialization strategy, outlines the analysts' views of Echo's market opportunity, and includes the analysts' estimates for Echo's future financial performance. Echo Therapeutics is making this announcement as a service to its shareholders and is not endorsing the report nor commenting on its contents.